Viridian Therapeutics, Inc. (VRDN)

NASDAQ: VRDN · IEX Real-Time Price · USD

12.16

-1.05 (-7.95%)

At close: Jul 2, 2024, 4:00 PM

12.05

-0.11 (-0.90%)

After-hours: Jul 2, 2024, 7:21 PM EDT

Viridian Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Net Income	-237.73	-129.87	-79.41	-110.72	-41.87	Upgrade
Depreciation & Amortization	0.57	0.29	0.02	0.24	0.29	Upgrade
Share-Based Compensation	67.17	19.77	14.47	3.65	3.97	Upgrade
Other Operating Activities	-14.18	15.98	10.35	77.05	1.56	Upgrade
Operating Cash Flow	-184.17	-93.84	-54.58	-29.78	-36.06	Upgrade
Capital Expenditures	-0.9	-0.8	-0.26	-0.04	-0.08	Upgrade
Acquisitions	0	0	0	29.37	0	Upgrade
Change in Investments	-93.35	-114.33	-74.03	-79.81	28.31	Upgrade
Other Investing Activities	-	-	-	-0	-	Upgrade
Investing Cash Flow	-94.25	-115.13	-74.29	-50.48	28.23	Upgrade
Share Issuance / Repurchase	139.58	276.68	109.61	23.76	2.4	Upgrade
Debt Issued / Paid	14.49	4.55	0	-8.57	-2.33	Upgrade
Other Financing Activities	71.6	41.01	15.67	86.12	-	Upgrade
Financing Cash Flow	225.67	322.24	125.28	101.31	0.07	Upgrade
Net Cash Flow	-52.75	113.28	-3.6	21.05	-7.76	Upgrade
Free Cash Flow	-185.07	-94.64	-54.84	-29.82	-36.14	Upgrade
Free Cash Flow Margin	-58938.85%	-5340.58%	-1850.83%	-2840.10%	-810.13%	Upgrade
Free Cash Flow Per Share	-4.13	-2.95	-4.60	-8.38	-17.30	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).